Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

WHO launches AMR diagnostic tools as national plans outpace funding

WHO released two AMR diagnostic tools as its 2026 survey exposed gaps in funded national plans and laboratory capacity.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

The World Health Organization released its 2026 antimicrobial resistance country survey and two diagnostic tools on November 16, pairing evidence of underfunded national plans with guidance for strengthening laboratory services. For university laboratories and public-health research partnerships, the Geneva-based agency’s announcement highlights the infrastructure needed to turn testing into reliable surveillance data.

National AMR plans outpace funded implementation

WHO’s November 16 release says 173 countries report having antimicrobial resistance action plans, compared with 79 in 2017. Only 22% report both the necessary financing and full implementation. The Tracking Antimicrobial Resistance Country Self-assessment Survey, or TrACSS, received responses from 183 countries, representing 94% of WHO member states.

Diagnostic capacity remains a central weakness. Just 36% of countries report a national reference laboratory equipped to test the selected bacteria and fungi. WHO also reports that 63% have guidelines on appropriate antimicrobial use. The findings distinguish having a national policy from maintaining the services and information systems needed to deliver it.

Two tools address different parts of the diagnostic system

A catalogue for planning diagnostic services

The 52-page Essential package of diagnostic tests for bacterial and fungal infections and antimicrobial resistance provides a prioritized catalogue organized by health-system level, from primary care to tertiary hospitals. It builds on WHO’s model list of essential in vitro diagnostics and is aimed at policymakers, regulators, providers and implementing partners.

Its planning framework connects test availability with national laboratory strategies, existing diagnostic networks, workforce capacity and sustainable financing. The implementation chapter covers governance, supply chains, quality assurance and monitoring. For institutions helping ministries develop laboratory services, that gives the catalogue a broader role than identifying equipment: it supports decisions about where services belong and how they will be sustained.

A toolkit for laboratory quality systems

The companion 24-page Toolkit of standard operating procedures for bacteriology, mycology and antimicrobial susceptibility testing addresses laboratory personnel, managers, quality staff and national networks. Its scope includes quality control, biosafety, equipment management, reporting and staff training.

WHO describes templates that laboratories can adopt or adapt to national requirements and local conditions, supported by review, verification or validation and continuing maintenance. The publication places those activities within existing quality-management and document-control arrangements. That makes the standard operating procedure a managed institutional document, with responsibilities and current versions, rather than simply a downloaded reference.

Surveillance expansion leaves a data integration gap

TrACSS is an annual self-assessment developed by WHO, the Food and Agriculture Organization, the UN Environment Programme and the World Organisation for Animal Health. Established in 2016, it tracks national implementation and informs monitoring of commitments made in the 2024 UN political declaration on AMR.

Reuters reporting by Mariam Sunny describes how surveillance has expanded: 113 countries now monitor antibiotic use and 109 track resistance, compared with 65 and 39 respectively in 2017. Yet only 21 countries reported integrating both datasets. Reuters reports WHO’s view that linking these data is important for understanding how antibiotic use drives resistance and for guiding national strategies.

For research teams, this separates two infrastructure questions: whether observations are collected and whether the resulting datasets can be used together. It is relevant to researchers interpreting sentinel surveillance, where the reporting network itself forms part of the evidence’s context.

WHO calls for delivery, with diagnostics at the centre

WHO Director-General Tedros Adhanom Ghebreyesus called for investment in infection prevention, surveillance and quality diagnostics, saying in the agency’s release that “an unfulfilled plan helps no one.”

In Chris Dall’s CIDRAP report, WHO officials emphasized the shift from adopting plans to delivering services. The briefing also connected inadequate testing with difficulty identifying where resistance is emerging. That is a research-data problem as well as a service-access problem: surveillance depends on laboratories being able to generate dependable observations.

AFP’s report, carried by Medical Xpress, likewise identified access to diagnostics as a major weakness and reported WHO officials’ warning that progress remained too slow for global targets. Its coverage placed the diagnostic tools alongside prevention and appropriate antimicrobial use in the wider response.

What changes for universities and research offices

For universities supporting national laboratory networks, the practical significance is a shared framework for discussing capacity. A partnership can use the diagnostic catalogue to relate proposed services to the health-system tier they support, while using the toolkit’s quality-management scope to define training and institutional responsibilities. These are planning implications of the publications, with implementation shaped by national and local requirements.

Research offices preparing infrastructure proposals have a concrete basis for discussing recurring support alongside capital spending. WHO’s implementation chapter includes equipment maintenance, workforce assessment, procurement, supply-chain continuity and monitoring. A laboratory-strengthening proposal therefore needs to explain how those functions will be supported throughout delivery.

For data managers, WHO’s package points to existing laboratory information systems and surveillance platforms as resources for monitoring implementation. That connects the role of a laboratory information management system with the wider reporting network. The toolkit’s emphasis on harmonized practices also makes comparability an explicit objective for institutions contributing data across sites.

Awareness week precedes the 2030 capacity target

The next dated milestone is World AMR Awareness Week, November 18–24. WHO’s 2026 theme, “One Health, one action: Prevent AMR now”, connects human, animal, plant and environmental health.

The longer-term benchmark is the global target for 80% of countries to have comprehensive bacterial and fungal resistance testing capacity by 2030. The publications give laboratory partners resources for implementation planning; the survey identifies how far funded delivery and diagnostic capacity still have to advance.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →